Ascend dabigatran capsules recalled for impurity specification failure
Ascend Laboratories is recalling one lot of dabigatran etexilate capsules, 150 mg, after an out-of-specification result in stability testing for Impurity II, Impurity III, and total impurities at 12 months. About 2,717 cartons were distributed nationwide by Major Pharmaceuticals. No injuries have been reported.
From the FDA notice · Read the official notice ↗ · All Ascend Laboratories recalls
What to do
- Talk to your pharmacist or prescriber before stopping this medicine.
- Check the carton for lot 25141584 and expiration date 4/30/2027 (NDC 0904-7255-10, 20-count carton, 2x10).
- The notice doesn't say how to get a refund or replacement; ask Major Pharmaceuticals or where you bought it.
Is yours affected?
Compare your label or packaging with the recalled product.
- Product
- Dabigatran etexilate Capsules, 150 mg, 20-count carton (2x10), Rx only, Manufactured by: Alkem Laboratories, Mumbai, INDIA, Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268, NDC 0904-7255-10.
- Sold in
- Nationwide
- Made for
- Adults (0 months and older)
This recall covers 2 products — see all of them.
Details
- Units affected
- 2,717 cartons
- Illnesses reported
- None reported
- Manufactured in
- 135 Us Highway 202 206 Ste 15, N/A, Bedminster, NJ, United States
- Classification
- Class III
- Recall number
- D-0736-2026
In the FDA's words
- Description
- Dabigatran etexilate Capsules, 150 mg, 20-count carton (2x10), Rx only, Manufactured by: Alkem Laboratories, Mumbai, INDIA, Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268, NDC 0904-7255-10. Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II, Impurity III and Total impurity testing for 12 Month Long-Term Stability. Lot: 25141584, Exp 4/30/2027. Distribution: USA Nationwide Affected quantity: 2,717 cartons
- Hazard
- Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II, Impurity III and Total impurity testing for 12 Month Long-Term Stability.
2 products in this recall
The agency lists each product separately. Check every one you might have.
- Dabigatran etexilate Capsules, 110 mg, 60-count carton (6x10), Rx Only, Manufactured by: Alkem Laboratories, Mumbai, INDIA, Distributed by: Major Pharmaceuti…D-0735-2026 · 1,753 cartons
- Dabigatran etexilate Capsules, 150 mg, 20-count carton (2x10), Rx only, Manufactured by: Alkem Laboratories, Mumbai, INDIA, Distributed by: Major Pharmaceuti… (this page)D-0736-2026 · 2,717 cartons
More from Ascend Laboratories
See all- Ascend amlodipine/olmesartan tablets recalled for failed dissolution
ModerateFDAOct 16, 2026